--- title: "Assessing Olympus (TSE:7733) Valuation After A Sharp Short-Term Share Price Rally" type: "News" locale: "en" url: "https://longbridge.com/en/news/288961980.md" description: "Olympus (TSE:7733) shares surged ~20% in a month, nearing analyst price targets. While reorganization aims to boost efficiency and margins, the stock is deemed slightly overvalued by ~1%. Key risks include challenges in China and high R&D spending potentially weighing on margins if scaling slows." datetime: "2026-06-07T13:38:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288961980.md) - [en](https://longbridge.com/en/news/288961980.md) - [zh-HK](https://longbridge.com/zh-HK/news/288961980.md) generator: "portal-rs" --- # Assessing Olympus (TSE:7733) Valuation After A Sharp Short-Term Share Price Rally ## Olympus stock overview after recent performance Olympus (TSE:7733) has drawn fresh attention after a strong run over the past month, with the stock up about 20% and roughly 35% over the past 3 months, prompting closer scrutiny of its medical equipment business. See our latest analysis for Olympus. The recent 20.1% 1 month share price return and 35.5% 3 month share price return contrast with a weaker year to date share price return and a 1 year total shareholder return that is slightly negative. This suggests momentum has picked up only in the short term. If Olympus has put healthcare on your radar, this is a good moment to scan the wider medical technology space through a dedicated set of 7 healthcare AI stocks. With Olympus stock now close to its analyst price target and trading slightly above one estimate of intrinsic value, is the recent surge overdone, or are investors still underestimating the company’s medical technology growth potential? ## Most Popular Narrative: 1% Overvalued Olympus last closed at ¥1,843.5, slightly above the most followed fair value estimate of ¥1,819.23, which is built using a 5.92% discount rate. > *The reorganization into more customer-focused divisions, including the creation of the Gastrointestinal Solutions Division (GIS) and the Surgical and Interventional Solutions Division (SIS), is expected to improve efficiency and execution. This change aims to drive market penetration and unlock recurring revenue streams, positively impacting revenue and net margins.* *Read the complete narrative.* Curious what kind of revenue profile and profit margins are baked into that fair value, and how long it takes to get there? The narrative leans on a specific path for earnings growth, a future profit margin step up and a valuation multiple that assumes Olympus keeps up with leading medtech peers. The exact mix of these ingredients may surprise you. **Result: Fair Value of ¥1,819.23 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points, including ongoing challenges in China and high R&D spending that could weigh on margins if new platforms scale more slowly than expected. Find out about the key risks to this Olympus narrative. ## Next Steps Does this mix of concerns and potential rewards feel balanced to you, or tilted one way? Act while the details are fresh and shape your own view by weighing the 1 key reward and 3 important warning signs ## Looking for more investment ideas? If Olympus has sharpened your interest, do not stop here. Widening your opportunity set with focused stock ideas can be just as important as analyzing one company. - Target steady compounding potential by scanning companies that combine quality with attractive pricing through the 12 high quality undervalued stocks. - Prioritize resilience by reviewing businesses with stronger balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (40 results). - Spot potential future standouts early by checking a screener containing 59 high quality undiscovered gems. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free ### Related Stocks - [7733.JP](https://longbridge.com/en/quote/7733.JP.md) ## Related News & Research - [10:12 ETOlympus anuncia un acuerdo de distribución global con Endocision para su sistema de criobiopsia respiratoria](https://longbridge.com/en/news/295812992.md) - [10:12 ETOlympus Announces Federal Healthcare Facility Distribution Agreement with First Nation Group](https://longbridge.com/en/news/290707729.md) - [07:11 ETMaxQ Medical Raises $31.5 Million Series A, Backed by Olympus, to Advance its Prostate Care Platform](https://longbridge.com/en/news/296480443.md) - [Is Hanwa (TSE:8078) Fully Valued On Fresh Earnings And Guidance?](https://longbridge.com/en/news/296298819.md) - [Is Starts (TSE:8850) Cheap As First Quarter Earnings And Guidance Reset Expectations?](https://longbridge.com/en/news/296635919.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**